Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Immunocore Holdings plc or Aurinia Pharmaceuticals Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Immunocore Holdings plc and Aurinia Pharmaceuticals Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Immunocore Holdings plc and Aurinia Pharmaceuticals Inc.

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 3 clinical trial to treat advanced cutaneous melanoma and adjuvant uveal melanoma; and brenetafusp that is in Phase 3 clinical trial to treat first-line advanced cutaneous melanoma and in a Phase 1/2 clinical trial in multiple tumor types. In addition, the company’s products under development include IMC-R117C (PIWIL-1) that is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, including colorectal cancer; IMC-P115C (PRAME-HLE-A02) that is in Phase 1 clinical trial for patients with tumors that express PRAME; IMC-M113V that is in Phase 1 clinical trials for a potential functional cure in human immunodeficiency virus (HIV); and IMC-I109V that is in Phase 1 clinical trials for a potential functional cure in hepatitis B virus (HBV). Further, it develops IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-S118AI to treat type 1 diabetes; and IMC-U120AI to treat atopic dermatitis. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Latest Biotechnology and Immunocore Holdings plc, Aurinia Pharmaceuticals Inc. Stock News

As of November 25, 2025, Immunocore Holdings plc had a $2.0 billion market capitalization, compared to the Biotechnology median of $209.4 million. Immunocore Holdings plc’s stock is up 36% in 2025, up 3.8% in the previous five trading days and up 19.34% in the past year.

Currently, Immunocore Holdings plc does not have a price-earnings ratio. Immunocore Holdings plc’s trailing 12-month revenue is $379.6 million with a -7.7% net profit margin. Year-over-year quarterly sales growth most recently was 29.3%. There are no analysts providing consensus earnings estimates for the current fiscal year. Immunocore Holdings plc does not currently pay a dividend.

As of November 25, 2025, Aurinia Pharmaceuticals Inc. had a $2.1 billion market cap, putting it in the 57th percentile of all stocks. Aurinia Pharmaceuticals Inc.’s stock is up 82.3% in 2025, up 7.7% in the previous five trading days and up 85.63% in the past year.

Currently, Aurinia Pharmaceuticals Inc.’s price-earnings ratio is 29.6. Aurinia Pharmaceuticals Inc.’s trailing 12-month revenue is $265.8 million with a 29.3% net profit margin. Year-over-year quarterly sales growth most recently was 8.4%. Analysts expect adjusted earnings to reach $0.782 per share for the current fiscal year. Aurinia Pharmaceuticals Inc. does not currently pay a dividend.

How We Compare Immunocore Holdings plc and Aurinia Pharmaceuticals Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Immunocore Holdings plc and Aurinia Pharmaceuticals Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Immunocore Holdings plc and Aurinia Pharmaceuticals Inc. Stock Value Grades

Company	Ticker	Value
Immunocore Holdings plc	IMCR	F
Aurinia Pharmaceuticals Inc.	AUPH	D

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Immunocore Holdings plc has a Value Score of 10, which is Ultra Expensive. Aurinia Pharmaceuticals Inc. has a Value Score of 36, which is Expensive.

The Value Stock Winner: No Clear Winner

Neither Immunocore Holdings plc or Aurinia Pharmaceuticals Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Immunocore Holdings plc or Aurinia Pharmaceuticals Inc. is the better investment when it comes to value.

Immunocore Holdings plc and Aurinia Pharmaceuticals Inc.’s Momentum Grades

Company	Ticker	Momentum
Immunocore Holdings plc	IMCR	B
Aurinia Pharmaceuticals Inc.	AUPH	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Immunocore Holdings plc has a Momentum Score of 72, which is Strong. Aurinia Pharmaceuticals Inc. has a Momentum Score of 90, which is Very Strong.

The Momentum Grade Winner: Aurinia Pharmaceuticals Inc.

As you can clearly see from the Momentum Grade breakdown above, Aurinia Pharmaceuticals Inc. is considered to have stronger momentum compared to Immunocore Holdings plc. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Aurinia Pharmaceuticals Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Immunocore Holdings plc and Aurinia Pharmaceuticals Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Immunocore Holdings plc	IMCR	C
Aurinia Pharmaceuticals Inc.	AUPH	B

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Immunocore Holdings plc has a Earnings Estimate Score of 51, which is Neutral. Aurinia Pharmaceuticals Inc. has a Earnings Estimate Score of 69, which is Positive.

The Earnings Estimate Revisions Grade Winner: Aurinia Pharmaceuticals Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Aurinia Pharmaceuticals Inc. has a better Earnings Estimate Revisions Grade than Immunocore Holdings plc. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Aurinia Pharmaceuticals Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Immunocore Holdings plc and Aurinia Pharmaceuticals Inc. Grades

In addition to Momentum, Value and Estimate Revisions, A+ Investor also provides grades for Growth and Quality.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Immunocore Holdings plc and Aurinia Pharmaceuticals Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Immunocore Holdings plc or Aurinia Pharmaceuticals Inc. Stock?

Overall, Immunocore Holdings plc stock has a Value Score of 10, Momentum Score of 72 and Estimate Revisions Score of 51.

Aurinia Pharmaceuticals Inc. stock has a Value Score of 36, Momentum Score of 90 and Estimate Revisions Score of 69.

Comparing Immunocore Holdings plc and Aurinia Pharmaceuticals Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.